Neuramedy
Biotechnology Research • 
20, Gwangnaru-ro 6-gil, Korea, Republic of • 1-10 Employees
Company overview
| Headquarters | 20, Gwangnaru-ro 6-gil, Seongdong-gu, #402 Eagle Town, Seoul, Seoul 04796, KR |
| Phone number | +8227653344 |
| Website | |
| NAICS | 541714 |
| Keywords | Parkinson'S, Neurodegeneration, Alpha Synuclein, Lewy Body, Tlr2, Synucleinopathy |
| Founded | 2019 |
| Employees | 1-10 |
| Socials |
Key Contact at Neuramedy
Minsup Lee
Co-CEO & Founder at Neuramedy
About Neuramedy
We are researching neuro-degenerative disorder focused on alpha synuclein. Our lead compound is Tomaraliman, a TLR2 agonist for Parkinsons' disease.
$
Neuramedy revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | $6,700,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
C-Suite
Employees by Department
Neuramedy has 1 employees across 1 departments.
Departments
Number of employees
Neuramedy Tech Stack
Discover the technologies and tools that power Neuramedy's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Operating systems
JavaScript libraries
Miscellaneous
Web servers
Maps
CDN
Germany
Ireland
United Kingdom
Sweden
United States
Japan
BelgiumFrequently asked questions
Neuramedy is located in 20, Gwangnaru-ro 6-gil, KR.
You can reach Neuramedy at +8227653344.
Neuramedy was founded in 2019, making it 7 years old. The company has established itself as a significant player in its industry over this time.
Neuramedy has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
Neuramedy has raised a total of $6,700,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.
4.8
40,000 users
